Glioma Stem Cells: Signaling, Microenvironment, and Therapy

Stem Cells International

Volumn 2016, Issue , 2016, Pages

  Liebelt, Brandon D ^a,b   Shingu, Takashi ^a   Zhou, Xin ^a   Ren, Jiangong ^a   Shin, Seul A ^a   Hu, Jian ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; BONE MORPHOGENETIC PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; ENDOGLIN; EPIDERMAL GROWTH FACTOR RECEPTOR; NERVE CELL ADHESION MOLECULE L1; NOTCH RECEPTOR; SONIC HEDGEHOG PROTEIN; STROMAL CELL DERIVED FACTOR 1; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; WNT PROTEIN;

ARTICLE; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SELF-RENEWAL; CELL SURVIVAL; CYTOKINE PRODUCTION; ENVIRONMENTAL FACTOR; GLIOBLASTOMA; GLIOMA STEM CELL; HUMAN; INTRACELLULAR SIGNALING; IONIZING RADIATION; MOLECULAR MIMICRY; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; TUMOR MICROENVIRONMENT;

EID: 84956473634     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2016/7849890     Document Type: Article

References (146)

1. M. D. Walker, S. B. Green, D. P. Byar et al., "Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery,"The New England Journal of Medicine, vol. 303, no. 23, pp. 1323-1329, 1980.
2. L. M. DeAngelis, "Brain tumors," The New England Journal of Medicine, vol. 344, no. 2, pp. 114-123, 2001.
3. R. Stupp, M. E. Hegi,W. P.Mason et al., "Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial," The Lancet Oncology, vol. 10, no. 5, pp. 459-466, 2009.
4. R. Stupp, W. P. Mason, M. J. VanDen Bent et al., "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma," The New England Journal of Medicine, vol. 352, no. 10, pp. 987-996, 2005.
5. S. A. Grossman and J. F. Batara, "Current management of glioblastoma multiforme," Seminars in Oncology, vol. 31, no. 5, pp. 635-644, 2004.
6. S. Bao, Q. Wu, R. E. McLendon et al., "Glioma stem cells promote radioresistance by preferential activation of the DNA damage response," Nature, vol. 444, no. 7120, pp. 756-760, 2006.
7. T. Reya, S. J. Morrison, M. F. Clarke, and I. L.Weissman, "Stem cells, cancer, and cancer stem cells," Nature, vol. 414, no. 6859, pp. 105-111, 2001.
8. D. Bonnet and J. E. Dick, "Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell," Nature Medicine, vol. 3, no. 7, pp. 730-737, 1997.
9. A. T. Collins, P. A. Berry, C. Hyde,M. J. Stower, andN. J.Maitland, "Prospective identification of tumorigenic prostate cancer stem cells," Cancer Research, vol. 65, no. 23, pp. 10946-10951, 2005.
10. L. Ricci-Vitiani, D. G. Lombardi, E. Pilozzi et al., "Identification and expansion of human colon-cancer-initiating cells," Nature, vol. 445, no. 7123, pp. 111-115, 2007.
11. C. F. B. Kim, E. L. Jackson, A. E. Woolfenden et al., "Identification of bronchioalveolar stem cells in normal lung and lung cancer," Cell, vol. 121, no. 6, pp. 823-835, 2005.
12. S. Zhang, C. Balch, M. W. Chan et al., "Identification and characterization of ovarian cancer-initiating cells from primary human tumors," Cancer Research, vol. 68, no. 11, pp. 4311-4320, 2008.
13. S. K. Singh, I. D. Clarke,M. Terasaki et al., "Identification of a cancer stem cell in human brain tumors," Cancer Research, vol. 63, no. 18, pp. 5821-5828, 2003.
14. S. J. Sundar, J. K. Hsieh, S. Manjila, J. D. Lathia, and A. Sloan, "The role of cancer stem cells in glioblastoma," Neurosurgical Focus, vol. 37, no. 6, article E6, 2014.
15. C.M.Morshead,B.A.Reynolds, C. G. Craig et al., "Neural stem cells in the adult mammalian forebrain: a relatively quiescent subpopulation of subependymal cells," Neuron, vol. 13,no. 5, pp. 1071-1082, 1994.
16. P. S. Eriksson, E. Perfilieva, T. Björk-Eriksson et al., "Neurogenesis in the adult human hippocampus," Nature Medicine, vol. 4, no. 11, pp. 1313-1317, 1998.
17. M. C. Nunes, N. S. Roy, H. M. Keyoung et al., "Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain," Nature Medicine, vol. 9, no. 4, pp. 439-447, 2003.
18. J. H. Globus and H. Kuhlenbeck, "The subependymal cell plate (matrix) and its relationship to brain tumors of the ependymal type," Journal of Neuropathology&Experimental Neurology, vol. 3, no. 1, pp. 1-35, 1944.
19. J.W. Hopewell and E. A. Wright, "The importance of implantation site in cerebral carcinogenesis in rats," Cancer Research, vol. 29, no. 11, pp. 1927-1931, 1969.
20. X. Yuan, J. Curtin, Y. Xiong et al., "Isolation of cancer stem cells from adult glioblastoma multiforme," Oncogene, vol. 23, no. 58, pp. 9392-9400, 2004.
21. D.D.Copeland andD.D. Bigner, "The role of the subependymal plate in avian sarcoma virus brain tumor induction: comparison of incipient tumors in neonatal and adult rats," Acta Neuropathologica, vol. 38, no. 1, pp. 1-6, 1977.
22. N. A. Vick, M.-J. Lin, and D. D. Bigner, "The role of the subependymal plate in glial tumorigenesis," Acta Neuropathologica, vol. 40, no. 1, pp. 63-71, 1977.
23. P. L. Lantos and D. J. Cox, "The origin of experimental brain tumours: a sequential study," Experientia, vol. 32, no. 11, pp. 1467-1468, 1976.
24. J. Hu, A. L. Ho, L. Yuan et al., "Neutralization of terminal differentiation in gliomagenesis," Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 36, pp. 14520-14527, 2013.
25. H. D. Hemmati, I. Nakano, J. A. Lazareff et al., "Cancerous stem cells can arise from pediatric brain tumors," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 25, pp. 15178-15183, 2003.
26. J. N. Rich and C. E. Eyler, "Cancer stem cells in brain tumor biology," Cold Spring Harbor Symposia on Quantitative Biology, vol. 73, pp. 411-420, 2008.
27. A. L. Vescovi, R. Galli, and B. A. Reynolds, "Brain tumour stem cells," Nature Reviews Cancer, vol. 6, no. 6, pp. 425-436, 2006.
28. S. Artavanis-Tsakonas, M. D. Rand, and R. J. Lake, "Notch signaling: cell fate control and signal integration in development," Science, vol. 284, no. 5415, pp. 770-776, 1999.
29. P. Beatus and U. Lendahl, "Notch and neurogenesis," Journal of Neuroscience Research, vol. 54, no. 2, pp. 125-136, 1998.
30. J. L. Lasky and H.Wu, "Notch signaling, brain development, and human disease," Pediatric Research, vol. 57,no. 5, pp. 104R-109R, 2005.
31. M. Kanamori, T. Kawaguchi, J.M. Nigro et al., "Contribution of Notch signaling activation to human glioblastomamultiforme," Journal of Neurosurgery, vol. 106, no. 3, pp. 417-427, 2007.
32. B. W. Purow, R. M. Haque, M. W. Noel et al., "Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation," Cancer Research, vol. 65, no. 6, pp. 2353-2363, 2005.
33. H.Kurooka, T.Nakahiro, K.Mori,K. Sano, and Y.Yokota, "BMP signaling is responsible for serum-induced Id2 expression," Biochemical and Biophysical Research Communications, vol. 420, no. 2, pp. 281-287, 2012.
34. F. Pistollato, H.-L. Chen, B. R. Rood et al., "Hypoxia and HIF1 repress the differentiative effects of BMPs in high-grade glioma," STEM CELLS, vol. 27, no. 1, pp. 7-17, 2009.
35. Q. Weng, Y. Chen, H. Wang et al., "Dual-mode modulation of Smad signaling by Smad-interacting protein Sip1 is required for myelination in the central nervous system," Neuron, vol. 73, no. 4, pp. 713-728, 2012.
36. M. Kasai, K. Satoh, and T. Akiyama, "Wnt signaling regulates the sequential onset of neurogenesis and gliogenesis via induction of BMPs," Genes to Cells, vol. 10, no. 8, pp. 777-783, 2005.
37. S. G. M. Piccirillo, B. A. Reynolds, N. Zanetti et al., "Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells," Nature, vol. 444, no. 7120, pp. 761-765, 2006.
38. L. Persano, F. Pistollato, E. Rampazzo et al., "BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1 stability and MGMT expression," Cell Death & Disease, vol. 3, no. 10, article e412, 2012.
39. K. Yan,Q.Wu,D.H. Yan et al., "Glioma cancer stem cells secrete Gremlin1 to promote their maintenance within the tumor hierarchy," Genes & Development, vol. 28, no. 10, pp. 1085-1100, 2014.
40. S. Paina, D. Garzotto, S. DeMarchis et al., "Wnt5a is a transcriptional target of Dlx homeogenes and promotes differentiation of interneuron progenitors in vitro and in vivo," The Journal of Neuroscience, vol. 31, no. 7, pp. 2675-2687, 2011.
41. Y. Pei, S.N. Brun, S. L.Markant et al., "WNTsignaling increases proliferation and impairs differentiation of stem cells in the developing cerebellum," Development, vol. 139, no. 10, pp. 1724-1733, 2012.
42. T. Grigoryan, P.Wend, A. Klaus, andW. Birchmeier, "Deciphering the function of canonical Wnt signals in development and disease: conditional loss-and gain-of-function mutations of -catenin in mice," Genes&Development, vol. 22,no. 17, pp. 2308-2341, 2008.
43. R. N.Munji, Y. Choe, G. Li, J. A. Siegenthaler, and S. J. Pleasure, "Wnt signaling regulates neuronal differentiation of cortical intermediate progenitors," The Journal of Neuroscience, vol. 31, no. 5, pp. 1676-1687, 2011.
44. R. J. Atkins, J. Dimou, L. Paradiso et al., "Regulation of glycogen synthase kinase-3 beta (GSK-3) by the Akt pathway in gliomas," Journal of Clinical Neuroscience, vol. 19, no. 11, pp. 1558-1563, 2012.
45. M. E.Hatten andM. F. Roussel, "Development and cancer of the cerebellum," Trends in Neurosciences, vol. 34, no. 3, pp. 134-142, 2011.
46. A. Bowman and R. Nusse, "Location, location, location: FoxM1 mediates α-catenin nuclear translocation and promotes glioma tumorigenesis," Cancer Cell, vol. 20, no. 4, pp. 415-416, 2011.
47. N. Zhang, P. Wei, A. Gong et al., "FoxM1 promotes -catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis," Cancer Cell, vol. 20, no. 4, pp. 427-442, 2011.
48. H. Zheng, H. Ying, R. Wiedemeyer et al., "PLAGL2 regulates Wnt signaling to impede differentiation in neural stemcells and gliomas," Cancer Cell, vol. 17, no. 5, pp. 497-509, 2010.
49. A. Ayuso-Sacido, J. A. Moliterno, S. Kratovac et al., "Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells," Journal of Neuro-Oncology, vol. 97, no. 3, pp. 323-337, 2010.
50. O. R. Lindberg, ? A. Persson, A. Brederlau, A. Shabro, and H. G. Kuhn, "EGF-induced expansion of migratory cells in the rostral migratory stream," PLoS ONE, vol. 7, no. 9, Article ID e46380, 2012.
51. R. Sanalkumar, S. Vidyanand, C. Lalitha Indulekha, and J. James, "Neuronal vs. glial fate of embryonic stem cell-derived neural progenitors (ES-NPs) is determined by FGF2/EGF during proliferation," Journal ofMolecular Neuroscience, vol. 42,no. 1, pp. 17-27, 2010.
52. J. Wang and R. K. Yu, "Interaction of ganglioside GD3 with an EGF receptor sustains the self-renewal ability of mouse neural stem cells in vitro," Proceedings of the National Academy of Sciences of theUnited States ofAmerica, vol. 110, no.47, pp. 19137-19142, 2013.
53. R. W. C. Wong, "Transgenic and knock-out mice for deciphering the roles of EGFR ligands," Cellular and Molecular Life Sciences, vol. 60, no. 1, pp. 113-118, 2003.
54. L. Lillien and H. Raphael, "BMP and FGF regulate the development of EGF-responsive neural progenitor cells," Development, vol. 127, no. 22, pp. 4993-5005, 2000.
55. W. Yang, Y. Xia, H. Ji et al., "Nuclear PKM2 regulates -catenin transactivation upon EGFR activation," Nature, vol. 480, no. 7375, pp. 118-122, 2011.
56. A. Ayuso-Sacido, C. Graham, J. P. Greenfield, and J. A. Boockvar, "The duality of epidermal growth factor receptor (EGFR) signaling and neural stem cell phenotype: cell enhancer or cell transformer?" Current Stem Cell Research & Therapy, vol. 1, no. 3, pp. 387-394, 2006.
57. F. Doetsch, L. Petreanu, I. Caille, J.-M. Garcia-Verdugo, and A. Alvarez-Buylla, "EGF converts transit-amplifying neurogenic precursors in the adult brain into multipotent stem cells," Neuron, vol. 36, no. 6, pp. 1021-1034, 2002.
58. M. K. Nicholas, R. V. Lukas, N. F. Jafri, L. Faoro, and R. Salgia, "Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas," Clinical Cancer Research, vol. 12, no. 24, pp. 7261-7270, 2006.
59. Y. Sun, S. K. Goderie, and S. Temple, "Asymmetric distribution of EGFR receptor duringmitosis generates diverseCNSprogenitor cells," Neuron, vol. 45, no. 6, pp. 873-886, 2005.
60. S.Agarwala, T. A. Sanders, and C.W.Ragsdale, "Sonichedgehog control of size and shape in midbrain pattern formation," Science, vol. 291, no. 5511, pp. 2147-2150, 2001.
61. C. Chiang, Y. Litingtung, E. Lee et al., "Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function," Nature, vol. 383, no. 6599, pp. 407-413, 1996.
62. H. Roelink, J. A. Porter, C. Chiang et al., "Floor plate andmotor neuron induction by different concentrations of the aminoterminal cleavage product of sonic hedgehog autoproteolysis," Cell, vol. 81, no. 3, pp. 445-455, 1995.
63. F. Balordi and G. Fishell, "Hedgehog signaling in the subventricular zone is required for both the maintenance of stem cells and themigration of newborn neurons,"TheJournal ofNeuroscience, vol. 27, no. 22, pp. 5936-5947, 2007.
64. R. A. Ihrie, J. K. Shah, C. C. Harwell et al., "Persistent sonic hedgehog signaling in adult brain determines neural stem cell positional identity," Neuron, vol. 71, no. 2, pp. 250-262, 2011.
65. E. E. Bar, A. Chaudhry, A. Lin et al., "Cyclopamine-mediated Hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma," Stem Cells, vol. 25, no. 10, pp. 2524-2533, 2007.
66. V. Clement, P. Sanchez, N. de Tribolet, I. Radovanovic, and A. Ruiz i Altaba, "HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity," Current Biology, vol. 17, no. 2, pp. 165-172, 2007.
67. M. E.Hardee andD. Zagzag, "Mechanisms of glioma-associated neovascularization,"TheAmerican Journal of Pathology, vol. 181, no. 4, pp. 1126-1141, 2012.
68. N. Jhaveri, T. C. Chen, and F. M. Hofman, "Tumor vasculature and glioma stem cells: contributions to glioma progression," Cancer Letters, 2014.
69. K. H. Plate, A. Scholz, and D. J. Dumont, "Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited," Acta Neuropathologica, vol. 124, no. 6, pp. 763-775, 2012.
70. W. Risau, "Mechanisms of angiogenesis," Nature, vol. 386, no. 6626, pp. 671-674, 1997.
71. J. Holash, P. C. Maisonpierre, D. Compton et al., "Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF," Science, vol. 284, no. 5422, pp. 1994-1998, 1999.
72. Y. Reiss, M. R.Machein, and K. H. Plate, "The role of angiopoietins during angiogenesis in gliomas," Brain Pathology, vol. 15, no. 4, pp. 311-317, 2005.
73. S. Bao, Q. Wu, S. Sathornsumetee et al., "Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor," Cancer Research, vol. 66, no. 16, pp. 7843-7848, 2006.
74. J.M.Heddleston, Z. Li, R. E.McLendon, A. B. Hjelmeland, and J. N. Rich, "The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype," Cell Cycle, vol. 8, no. 20, pp. 3274-3284, 2009.
75. Y.-F. Ping, X.-H. Yao, J.-Y. Jiang et al., "The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling," Journal of Pathology, vol. 224, no. 3, pp. 344-354, 2011.
76. C. Folkins, Y. Shaked, S. Man et al., "Glioma tumor stemlike cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1," Cancer Research, vol. 69, no. 18, pp. 7243-7251, 2009.
77. C. Thirant, E.-M. Galan-Moya, L. G. Dubois et al., "Differential proteomic analysis of human glioblastoma and neural stemcells reveals HDGF as a novel angiogenic secreted factor," StemCells, vol. 30, no. 5, pp. 845-853, 2012.
78. J. Folkman and Y. Shing, "Angiogenesis," The Journal of Biological Chemistry, vol. 267, no. 16, pp. 10931-10934, 1992.
79. T. Asahara, T.Murohara, A. Sullivan et al., "Isolation of putative progenitor endothelial cells for angiogenesis," Science, vol. 275, no. 5302, pp. 964-966, 1997.
80. C. E. Lewis, M. De Palma, and L. Naldini, "Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2," Cancer Research, vol. 67, no. 18, pp. 8429-8432, 2007.
81. M. A.Venneri, M.De Palma, M. Ponzoni et al., "Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer," Blood, vol. 109, no. 12, pp. 5276-5285, 2007.
82. R. Du, K. V. Lu, C. Petritsch et al., "HIF1 induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion," Cancer Cell, vol. 13, no. 3, pp. 206-220, 2008.
83. L. Ricci-Vitiani, R. Pallini, M. Biffoni et al., "Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells," Nature, vol. 468, no. 7325, pp. 824-828, 2010.
84. L. Kilburn, M. F. Okcu, T. Wang et al., "Glutathione Stransferase polymorphisms are associated with survival in anaplastic glioma patients," Cancer, vol. 116, no. 9, pp. 2242-2249, 2010.
85. R.Wang, K. Chadalavada, J.Wilshire et al., "Glioblastoma stemlike cells give rise to tumour endothelium," Nature, vol. 468, no. 7325, pp. 829-835, 2010.
86. Y. Soda, T. Marumoto, D. Friedmann-Morvinski et al., "Transdifferentiation of glioblastoma cells into vascular endothelial cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 11, pp. 4274-4280, 2011.
87. F. J. Rodriguez, B. A. Orr, K. L. Ligon, and C. G. Eberhart, "Neoplastic cells are a rare component in human glioblastoma microvasculature," Oncotarget, vol. 3, no. 1, pp. 98-106, 2012.
88. M. R.Machein, S. Renninger, E.De Lima-Hahn, andK.H. Plate, "Minor contribution of bone marrow-derived endothelial progenitors to the vascularization ofmurine gliomas," Brain Pathology, vol. 13, no. 4, pp. 582-597, 2003.
89. A. Armulik, G. Genové, and C. Betsholtz, "Pericytes: developmental, physiological, and pathological perspectives, problems, and promises," Developmental Cell, vol. 21, no. 2, pp. 193-215, 2011.
90. L. Cheng, Z. Huang, W. Zhou et al., "Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth," Cell, vol. 153, no. 1, pp. 139-152, 2013.
91. P.-O. Guichet, S. Guelfi, M. Teigell et al., "Notch1 stimulation induces a vascularization switch with pericyte-like cell differentiation of glioblastoma stem cells," Stem Cells, vol. 33, no. 1, pp. 21-34, 2014.
92. M. J. C. Hendrix, E. A. Seftor, A. R. Hess, and R. E. B. Seftor, "Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma," Nature Reviews Cancer, vol. 3, no. 6, pp. 411-421, 2003.
93. A. J. Maniotis, R. Folberg, A. Hess et al., "Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry,"TheAmerican Journal of Pathology, vol. 155, no. 3, pp. 739-752, 1999.
94. W.-Y. Yue and Z.-P. Chen, "Does vasculogenic mimicry exist in astrocytoma?" Journal of Histochemistry & Cytochemistry, vol. 53, no. 8, pp. 997-1002, 2005.
95. J.-M. Mao, J. Liu, G. Guo, X. Mao, and C. Li, "Glioblastoma vasculogenic mimicry: signaling pathways progression and potential anti-angiogenesis targets," Biomarker Research, vol. 3, no. 1, article 8, 2015.
96. J.Dong, Q. Zhang, Q. Huang et al., "Glioma stem cells involved in tumor tissue remodeling in a xenograft model: laboratory investigation," Journal of Neurosurgery, vol. 113, no. 2, pp. 249-260, 2010.
97. S. El Hallani, B. Boisselier, F. Peglion et al., "A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry," Brain, vol. 133, no. 4, pp. 973-982, 2010.
98. Y. Chen, Z. Jing, C. Luo et al., "Vasculogenic mimicry-potential target for glioblastoma therapy: an in vitro and in vivo study," Medical Oncology, vol. 29, no. 1, pp. 324-331, 2012.
99. X.Yao,Y. Ping, Y. Liu et al., "Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by glioma stem-like cells," PLoS ONE, vol. 8, no. 3,Article ID e57188, 2013.
100. X.-G. Mao, X.-Y. Xue, L. Wang et al., "CDH5 is specifically activated in glioblastoma stemlike cells and contributes to vasculogenic mimicry induced by hypoxia," Neuro-Oncology, vol. 15, no. 7, pp. 865-879, 2013.
101. J. Chen, Y. Li, T.-S. Yu et al., "A restricted cell population propagates glioblastoma growth after chemotherapy," Nature, vol. 488, no. 7412, pp. 522-526, 2012.
102. N. Sanai and M. S. Berger, "Glioma extent of resection and its impact on patient outcome," Neurosurgery, vol. 62, no. 4, pp. 753-764, 2008.
103. B. Auffinger, D. Spencer, P. Pytel, A. U. Ahmed, andM. S. Lesniak, "The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence," Expert Review of Neurotherapeutics, vol. 15, no. 7, pp. 741-752, 2015.
104. D. Hambardzumyan, M. Squartro, and E. C. Holland, "Radiation resistance and stem-like cells in brain tumors," Cancer Cell, vol. 10, no. 6, pp. 454-456, 2006.
105. E. R. Blazek, J. L. Foutch, andG.Maki, "Daoymedulloblastoma cells that express CD133 are radioresistant relative to CD133-cells, and the CD133+ sector is enlarged by hypoxia," International Journal of Radiation Oncology Biology Physics, vol. 67, no. 1, pp. 1-5, 2007.
106. A.-M. Bleau, D. Hambardzumyan, T. Ozawa et al., "PTEN/ PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells," Cell Stem Cell, vol. 4, no. 3, pp. 226-235, 2009.
107. B.-B. S. Zhou and S. J. Elledge, "The DNA damage response: putting checkpoints in perspective," Nature, vol. 408, no. 6811, pp. 433-439, 2000.
108. A. M. McCord,M. Jamal, E. S.Williams, K. Camphausen, and P. J. Tofilon, "CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines," Clinical Cancer Research, vol. 15, no. 16, pp. 5145-5153, 2009.
109. K. Ochs and B. Kaina, "Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent," Cancer Research, vol. 60,no. 20,pp. 5815-5824, 2000.
110. M. E.Hegi, A.-C. Diserens, T.Gorlia et al., "MGMTgene silencing and benefit from temozolomide in glioblastoma," The New England Journal of Medicine, vol. 352, no. 10, pp. 997-1003, 2005.
111. M. E. Hegi, L. Liu, J. G. Herman et al., "Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity," Journal of Clinical Oncology, vol. 26, no. 25, pp. 4189-4199, 2008.
112. M. Okada, A. Sato, K. Shibuya et al., "JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression," International Journal of Oncology, vol. 44, no. 2, pp. 591-599, 2014.
113. L. Persano, F. Pistollato, E. Rampazzo et al., "BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1alpha stability andMGMT expression," Cell Death and Disease, vol. 3, article e412, 2012.
114. J. Wang, T. P. Wakeman, J. D. Lathia et al., "Notch promotes radioresistance of glioma stem cells," Stem Cells, vol. 28, no. 1, pp. 17-28, 2010.
115. I. V. Ulasov, S. Nandi, M. Dey, A. M. Sonabend, and M. S. Lesniak, "Inhibition of sonic hedgehog and notch pathways enhances sensitivity of CD133+ glioma stem cells to temozolomide therapy," Molecular Medicine, vol. 17, no. 1-2, pp. 103-112, 2011.
116. R. G. W. Verhaak, K. A. Hoadley, E. Purdom et al., "Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1," Cancer Cell, vol. 17, no. 1, pp. 98-110, 2010.
117. J. M. Stommel, A. C. Kimmelman, H. Ying et al., "Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies," Science, vol. 318, no. 5848, pp. 287-290, 2007.
118. F. Pistollato, S. Abbadi, E. Rampazzo et al., "Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma," STEM CELLS, vol. 28, no. 5, pp. 851-862, 2010.
119. Z. Li, S. Bao, Q. Wu et al., "Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells," Cancer Cell, vol. 15, no. 6, pp. 501-513, 2009.
120. S. Seidel, B. K. Garvalov, V. Wirta et al., "A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 " Brain, vol. 133, no. 4, pp. 983-995, 2010.
121. J. Kolenda, S. S. Jensen, C. Aaberg-Jessen et al., "Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids," Journal of Neuro-Oncology, vol. 103, no. 1, pp. 43-58, 2011.
122. A. Eramo, L. Ricci-Vitiani, A. Zeuner et al., "Chemotherapy resistance of glioblastoma stem cells," Cell Death and Differentiation, vol. 13, no. 7, pp. 1238-1241, 2006.
123. L. Shi, S. Zhang, K. Feng et al., "MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis," International Journal of Oncology, vol. 40, no. 1, pp. 119-129, 2012.
124. P. Brescia, B. Ortensi, L. Fornasari, D. Levi, G. Broggi, and G. Pelicci, "CD133 is essential for glioblastoma stem cell maintenance," STEM CELLS, vol. 31, no. 5, pp. 857-869, 2013.
125. I. Shibahara, Y. Sonoda, R. Saito et al., "The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence," Neuro-Oncology, vol. 15, no. 9, pp. 1151-1159, 2013.
126. C.-H.Wang, S.-H. Chiou, C.-P. Chou, Y.-C. Chen, Y.-J. Huang, and C.-A. Peng, "Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody," Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 7, no. 1, pp. 69-79, 2011.
127. D. R. Emlet, P. Gupta, M. Holgado-Madruga et al., "Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III," Cancer Research, vol. 74, no. 4, pp. 1238-1249, 2014.
128. Y.-J. Boo, J.-M. Park, J. Kim et al., "L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer," Annals of Surgical Oncology, vol. 14, no. 5, pp. 1703-1711, 2007.
129. S. Izumoto, T. Ohnishi, N. Arita, S. Hiraga, T. Taki, and T. Hayakawa, "Gene expression of neural cell adhesion molecule L1 in malignant gliomas and biological significance of L1 in glioma invasion," Cancer Research, vol. 56, no. 6, pp. 1440-1444, 1996.
130. S. Bao, Q.Wu, Z. Li et al., "Targeting cancer stem cells through L1CAMsuppresses glioma growth," Cancer Research, vol. 68,no. 15, pp. 6043-6048, 2008.
131. H. S. Günther, N. O. Schmidt, H. S. Phillips et al., "Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria," Oncogene, vol. 27, no. 20, pp. 2897-2909, 2008.
132. A. T. Ogden, A. E. Waziri, R. A. Lochhead et al., "Identification of A2B5+CD133? tumor-initiating cells in adult human gliomas," Neurosurgery, vol. 62, no. 2, pp. 505-515, 2008.
133. N. Gaiano and G. Fishell, "The role of notch in promoting glial and neural stem cell fates," Annual Review of Neuroscience, vol. 25, no. 1, pp. 471-490, 2002.
134. X. Fan, W. Matsui, L. Khaki et al., "Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors," Cancer Research, vol. 66, no. 15, pp. 7445-7452, 2006.
135. O. A. Guryanova, Q.Wu, L. Cheng et al., "Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3," Cancer Cell, vol. 19, no. 4, pp. 498-511, 2011.
136. M. Kortylewski, M. Kujawski, A. Herrmann et al., "Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy," Cancer Research, vol. 69, no. 6, pp. 2497-2505, 2009.
137. A. Herrmann, G. Cherryholmes, A. Schroeder et al., "TLR9 is critical for glioma stemcellmaintenance and targeting," Cancer Research, vol. 74, no. 18, pp. 5218-5228, 2014.
138. A. S. Chung and N. Ferrara, "Developmental and pathological angiogenesis," Annual Review of Cell and Developmental Biology, vol. 27, pp. 563-584, 2011.
139. C. Calabrese, H. Poppleton, M. Kocak et al., "A perivascular niche for brain tumor stem cells," Cancer Cell, vol. 11, no. 1, pp. 69-82, 2007.
140. B. Badie and J. Schartner, "Role of microglia in glioma biology," Microscopy Research and Technique, vol. 54, no. 2, pp. 106-113, 2001.
141. S. F.Hussain,D. Yang,D. Suki, E.Grimm, andA. B.Heimberger, "Innate immune functions of microglia isolated from human glioma patients," Journal of Translational Medicine, vol. 4, no. 1, article 15, 2006.
142. B. C. Kennedy, L. M. Maier, R. D'Amico et al., "Dynamics of central and peripheral immunomodulation in a murine glioma model," BMC Immunology, vol. 10, no. 1, article 11, 2009.
143. W. Li and M. B. Graeber, "The molecular profile of microglia under the influence of glioma," Neuro-Oncology, vol. 14, no. 8, pp. 958-978, 2012.
144. S. Wagner, S. Czub, M. Greif et al., "Microglial/macrophage expression of interleukin 10 in human glioblastomas," International Journal of Cancer, vol. 82, no. 1, pp. 12-16, 1999.
145. S. M. Pyonteck, L. Akkari, A. J. Schuhmacher et al., "CSF-1R inhibition alters macrophage polarization and blocks glioma progression," Nature Medicine, vol. 19, no. 10, pp. 1264-1272, 2013.
146. W. Zhou, S. Q. Ke, Z. Huang et al., "Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth," Nature Cell Biology, vol. 17, no. 2, pp. 170-182, 2015.